| value |
{"aggregator_url":"https://www.nasdaq. {"aggregator_url":"https://www.nasdaq.com/articles/dianthus-therapeutics-cfo-sells-95-million-stock","as_of":"2026-04-06T21:04:57.701497+00:00","canonical_url":"https://www.fool.com/coverage/filings/2026/04/06/dianthus-therapeutics-cfo-sells-usd9-5-million-in-stock/","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/dianthus-therapeutics-cfo-sells-95-million-stock","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_aba6608e82a38759","canonical_host":"fool.com","canonical_is_aggregator":false,"canonical_url":"https://www.fool.com/coverage/filings/2026/04/06/dianthus-therapeutics-cfo-sells-usd9-5-million-in-stock/","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-07T15:32:49.489511+00:00","extraction_method":"heuristic","fetched_description":"Key Points114,367 shares were sold for a transaction value of approximately $9.49 million on March 31, 2026.","fetched_title":"Dianthus Therapeutics CFO Sells $9.5 Million in Stock | Nasdaq","final_url":"https://www.nasdaq.com/articles/dianthus-therapeutics-cfo-sells-95-million-stock","html_truncated":false,"paywall_likely":false,"publisher_domain":"fool.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/dianthus-therapeutics-cfo-sells-95-million-stock","source_event_id":"evt_026d0d4a7a4e","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"2e1d8a10813a2a7d","kind":"unusual_volume","published_at":"2026-04-06T19:47:17+00:00","publisher_domain":"fool.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.9,"dates_mentioned":["March 31, 2026","April 1, 2026"],"entities":[{"asset_class":"equity","name":"Dianthus Therapeutics","relevance":"high","symbol":"DNTH","type":"company"}],"event_type":"other","information_gaps":["No baseline volume data provided for unusual volume analysis.","No confirmation of news impact on stock price movement."],"key_facts":["114,367 shares sold for $9.49 million on March 31, 2026.","Transaction reduced Savitz's direct ownership to zero.","Savitz retains 90,399 stock options for future equity participation."],"numeric_claims":[{"label":"shares sold","value":"114,367"},{"label":"transaction value","value":"$9.49 million"}],"primary_claim":"Ryan Savitz sold 114,367 shares of Dianthus Therapeutics for $9.49 million, representing 100% of his direct common stock holdings.","relevance_score":0.8,"sentiment":"neutral","source_quality":"high","summary":"Dianthus Therapeutics CFO Ryan Savitz sold 114,367 shares for approximately $9.49 million, reducing his direct ownership to zero, while retaining stock options for future equity participation.","topics":["insider trading","stock options","biotechnology"]},"source":"Nasdaq Markets","source_domain":"fool.com","summary":"Key Points114,367 shares were sold for a transaction value of approximately $9.49 million on March 31, 2026.","tickers":[],"title":"Dianthus Therapeutics CFO Sells $9.5 Million in Stock","url":"https://www.fool.com/coverage/filings/2026/04/06/dianthus-therapeutics-cfo-sells-usd9-5-million-in-stock/"}... |